We are pleased to announce a worldwide capacity reservation and supply agreement with Cellares for the manufacture of CAR T cell therapies – Bristol Myers Squibb

Bristol Myers Squibb shared a post on LinkedIn:

“We are pleased to announce a worldwide capacity reservation and supply agreement with Cellares for the manufacture of CAR T cell therapies, giving us access to a next-generation fully automated, end-to-end cell therapy manufacturing platform. As part of the agreement, Cellares will optimize and automate select BMS CAR T cell therapies onto its manufacturing platform, the Cell Shuttle. We look forward to our continued work with Cellares and to the promise this agreement will bring for patients benefiting from CAR T therapies.”

Source: Bristol Myers Squibb/LinkedIn